Loading...
XNASPCRX
Market cap953mUSD
Jan 10, Last price  
20.64USD
1D
11.09%
1Q
27.25%
Jan 2017
-36.10%
IPO
193.60%
Name

Pacira Biosciences Inc

Chart & Performance

D1W1MN
XNAS:PCRX chart
P/E
22.72
P/S
1.41
EPS
0.91
Div Yield, %
0.00%
Shrs. gr., 5y
4.91%
Rev. gr., 5y
14.88%
Revenues
675m
+1.22%
13,925,00015,006,00014,562,00015,689,00039,084,00085,551,000197,668,000248,997,000276,371,000286,630,000337,277,000421,026,000420,830,000541,533,000666,823,000674,978,000
Net income
42m
+163.72%
-41,862,000-31,707,000-27,149,000-43,328,000-52,281,000-63,909,000-13,716,0001,856,000-37,949,000-42,611,000-471,000-11,016,000145,523,00041,980,00015,909,00041,955,000
CFO
155m
+6.45%
-29,189,000-20,838,000-24,880,000-31,000,000-70,130,000-43,216,00025,469,00028,996,00033,453,00017,785,00048,870,00070,520,00077,032,000125,717,000145,274,000154,649,000
Earnings
Feb 26, 2025

Profile

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
URL
https://www.pacira.com/
IPO date
Feb 03, 2011
Employees
715
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
674,978
1.22%
666,823
23.14%
Cost of revenue
530,367
538,608
Unusual Expense (Income)
NOPBT
144,611
128,215
NOPBT Margin
21.42%
19.23%
Operating Taxes
19,746
(2,607)
Tax Rate
13.65%
NOPAT
124,865
130,822
Net income
41,955
163.72%
15,909
-62.10%
Dividends
Dividend yield
Proceeds from repurchase of equity
(106)
30,295
BB yield
0.01%
-1.69%
Debt
Debt current
17,442
42,769
Long-term debt
632,209
794,548
Deferred revenue
Other long-term liabilities
38,271
37,791
Net debt
368,660
484,287
Cash flow
Cash from operating activities
154,649
145,274
CAPEX
(15,161)
(30,076)
Cash from investing activities
77,541
(225,185)
Cash from financing activities
(183,031)
(401,528)
FCF
97,513
107,678
Balance
Cash
278,581
288,651
Long term investments
2,410
64,379
Excess cash
247,242
319,689
Stockholders' equity
(106,503)
(149,085)
Invested Capital
1,600,948
1,725,280
ROIC
7.51%
6.75%
ROCE
9.68%
8.13%
EV
Common stock shares outstanding
51,979
46,538
Price
33.74
-12.61%
38.61
-35.83%
Market cap
1,753,771
-2.40%
1,796,832
-34.55%
EV
2,122,431
2,281,119
EBITDA
220,185
219,716
EV/EBITDA
9.64
10.38
Interest
20,306
39,976
Interest/NOPBT
14.04%
31.18%